Upstream Bio Inc. (UPB)
NASDAQ: UPB
· Real-Time Price · USD
9.18
-0.13 (-1.40%)
At close: May 23, 2025, 3:59 PM
9.16
-0.22%
After-hours: May 23, 2025, 04:04 PM EDT
-1.40% (1D)
| Bid | 8.5 |
| Market Cap | 493.83M |
| Revenue (ttm) | 2.3M |
| Net Income (ttm) | -79.18M |
| EPS (ttm) | -1.67 |
| PE Ratio (ttm) | -5.5 |
| Forward PE | -3.2 |
| Analyst | Buy |
| Ask | 10.85 |
| Volume | 261,507 |
| Avg. Volume (20D) | 294,985 |
| Open | 9.11 |
| Previous Close | 9.31 |
| Day's Range | 8.91 - 9.71 |
| 52-Week Range | 5.14 - 29.46 |
| Beta | 0.10 |
Analyst Forecast
According to 0 analyst ratings, the average rating for UPB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+7.83%
Upstream Bio shares are trading lower after the co...
Unlock content with
Pro Subscription
6 months ago
+8.91%
Upstream shares are trading higher after multiple firms initiated coverage on the stock with an Overweight rating.
1 month ago · seekingalpha.com
Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is ImminentUpstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of...